» Articles » PMID: 35684543

The GABAergic System and Endocannabinoids in Epilepsy and Seizures: What Can We Expect from Plant Oils?

Abstract

Seizures and epilepsy are some of the most common serious neurological disorders, with approximately 80% of patients living in developing/underdeveloped countries. However, about one in three patients do not respond to currently available pharmacological treatments, indicating the need for research into new anticonvulsant drugs (ACDs). The GABAergic system is the main inhibitory system of the brain and has a central role in seizures and the screening of new ACD candidates. It has been demonstrated that the action of agents on endocannabinoid receptors modulates the balance between excitatory and inhibitory neurotransmitters; however, studies on the anticonvulsant properties of endocannabinoids from plant oils are relatively scarce. The Amazon region is an important source of plant oils that can be used for the synthesis of new fatty acid amides, which are compounds analogous to endocannabinoids. The synthesis of such compounds represents an important approach for the development of new anticonvulsant therapies.

Citing Articles

New Pharmacological Therapies in the Treatment of Epilepsy in the Pediatric Population.

Danilowska K, Picheta N, Zyla D, Piekarz J, Zych K, Gil-Kulik P J Clin Med. 2024; 13(12).

PMID: 38930098 PMC: 11204858. DOI: 10.3390/jcm13123567.


Lippia origanoides essential oil possesses anticonvulsant effect in pentylenetetrazol-induced seizures in rats: a behavioral, electroencephalographic, and electromyographic study.

de Araujo D, do Amaral A, da Fonseca S, de Souza K, da Paz A, de Mello V Front Pharmacol. 2023; 14:1289336.

PMID: 38089062 PMC: 10715423. DOI: 10.3389/fphar.2023.1289336.


Commonalities for comorbidity: Overlapping features of the endocannabinoid system in depression and epilepsy.

Epps S Front Psychiatry. 2022; 13:1041460.

PMID: 36339877 PMC: 9626804. DOI: 10.3389/fpsyt.2022.1041460.


Virtual Screening-Based Drug Development for the Treatment of Nervous System Diseases.

Li Q, Ma Z, Qin S, Zhao W Curr Neuropharmacol. 2022; 21(12):2447-2464.

PMID: 36043797 PMC: 10616913. DOI: 10.2174/1570159X20666220830105350.

References
1.
Ravizza T, Boer K, Redeker S, Spliet W, van Rijen P, Troost D . The IL-1beta system in epilepsy-associated malformations of cortical development. Neurobiol Dis. 2006; 24(1):128-43. DOI: 10.1016/j.nbd.2006.06.003. View

2.
Fezza F, Marrone M, Avvisati R, Di Tommaso M, Lanuti M, Rapino C . Distinct modulation of the endocannabinoid system upon kainic acid-induced in vivo seizures and in vitro epileptiform bursting. Mol Cell Neurosci. 2014; 62:1-9. DOI: 10.1016/j.mcn.2014.07.003. View

3.
Shneker B, Fountain N . Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. Neurology. 2003; 61(8):1066-73. DOI: 10.1212/01.wnl.0000082653.40257.0b. View

4.
Garcia-Fernandez M . [Epileptic spasms in infants. Beyond hypsarrhythmia]. Rev Neurol. 2017; 64(s03):S55-S59. View

5.
Kandratavicius L, Balista P, Lopes-Aguiar C, Ruggiero R, Umeoka E, Garcia-Cairasco N . Animal models of epilepsy: use and limitations. Neuropsychiatr Dis Treat. 2014; 10:1693-705. PMC: 4164293. DOI: 10.2147/NDT.S50371. View